2-Amino-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one, 97%, 5g

Diapositiva de contraste de fase con anillos de fase para objetivos de fase de plan de aceite PLPH 20x y S100x

1-(3-BETA-AMINO-2,3-DIDEOXY-BETA-D-THREOPENTA-FURANOSYL)THYMINE, 95.0%, 100mg

2-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine, 95.0%, 25g

trans,trans-4-n-Propyl-4'-[4-(trifluoromethoxy)phenyl]bicyclohexyl, 97%, 25g

tert-Butyl 2-oxa-3-azabicyclo[2.2.1]hept-5-ene-3-carboxylate, 95.0%, 25g

2-Fluoro-5-(trifluoromethyl)pyridin-3-ol, 97%, 100mg

5,5-Difluorotetrahydropyran-3-amine hydrochloride, 98%, 250mg

3-(4-Chlorophenyl)cyclohex-2-en-1-one, 95%, 2.5g

2-Bromo-4-(tert-butyl)pyridine, 95.0%, 10g

N-(4-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)PHENYL)ACETAMIDE, 95.0%, 250mg

6-Boc-Hydrazynonicotinic acid, 95.0%, 1g

Yoduro de 2-butiriltiocolina, mín. 99 %, para bioquímica, 10 g, envase de vidrio